Dr. Clay Siegall Talks About Moving Away From Partnerships At Seattle Genetics

Dr. Clay Siegall is a leader in the biotechnology industry. He founded Seattle Genetics in 1998. He leads this company as its CEO and chairman. Seattle Genetics develops targeted drug therapies for diseases, such as some forms of cancer, which haven’t seen any improvement in people surviving them in the past few decades. His specialty is antibody drug conjugates (ADC) and Seattle Genetics was the first biotech firm to receive FDA-approval for one of these, in this case their drug Adcetris which is a treatment for lymphoma.

When Dr. Clay Siegall established Seattle Genetics he says that it had a very small staff. Since that time they are one of the leading companies when it comes to cancer research. His company has over 20 drugs in development everywhere from the earliest stages to clinical trials. He says that drugs like the ones his company makes will replace systemic chemotherapies at some point in the coming decades as patients can both tolerate them better and because they are a lot more effective at irradicating diseases.

To this point Dr. Clay Siegall has used partnerships to get his company’s products on the market. He says that starting out Seattle Genetics didn’t really have any staff that were experts in marketing, distribution, and areas such as that. Adcetris, for instance, is marketed and distributed by another company called Takada Pharmaceuticals. He’s also formed partnerships with major players in the healthcare industry like Pfizer and Bayer.

Now that his company is maturing, Dr. Clay Siegall says that his company can move away from partnering with other firms. He says that they completely own one ADC they have under development to treat breast cancer, for example. Once it receives approval he plans to launch this drug themselves in both America and around the world.

In order to do clinical trials internationally Dr. Clay Siegall said his company recently opened an office in Switzerland called SeaGen International GmbH. He said he did this so that they could receive European approval for his company’s drugs quicker. He wants both his drug development and commercial efforts to now be global in nature.